)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CellaVision
CellaVision (CEVI) investor relations material
CellaVision Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 net sales were SEK 199.5m, up 13.6% YoY with 13.4% organic growth; EBITDA was SEK 64m and EBITDA margin reached 32%.
Americas and APAC led growth; EMEA declined against a strong prior-year comparison. Q3 operating cash flow more than doubled to SEK 68.1m.
Financial highlights
Gross margin was 66% versus 69% YoY; operating expenses were SEK 82m, or 41% of sales, and included SEK 4m in final CEO-transition settlement costs.
Amortization of capitalized development costs was SEK 5m versus SEK 2m YoY; the increase was charged to cost of goods sold.
9M net sales were SEK 565.8m versus SEK 561.8m; EBITDA was SEK 158.8m versus SEK 175.9m, and operating profit was SEK 120.1m versus SEK 147.0m.
Q3 net profit was SEK 40.2m versus SEK 31.3m; diluted and undiluted EPS were SEK 1.68 versus SEK 1.31.
Segment performance
Americas sales rose 32% to SEK 89m, supported by connected platforms, software, a Canadian tender and installed-base replacements.
EMEA sales fell 10% to SEK 86m against a strong Q3 2025 comparison; BMA Application revenue and reagent sales grew.
APAC sales rose 90% to SEK 24m, with 91% organic growth; performance outside China was solid, including strong reagent sales and conversion in Japan.
Instrument sales increased 14% to SEK 105m; reagents rose 12% to SEK 45m, and Software & Other increased 15% to SEK 49m.
9M sales rose 30% in Americas to SEK 274m, fell 16% in EMEA to SEK 227m, and declined 18% in APAC to SEK 65m.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CellaVision
- Record Americas sales and innovation drive growth, despite EMEA and APAC headwinds.CEVI
Q2 2026 - Sales fell 14.6% as EMEA dropped, but Americas and APAC posted strong organic growth.CEVIQ1 2026
- Strong Q4 growth in Americas, stable margins, and higher dividend proposed; new launches in 2026.CEVIQ4 2025
- Margins improved and organic growth continued despite softer sales and currency headwinds.CEVIQ3 2025
- Organic growth reached 7.6% with APAC leading, and gross margin improved to 68%.CEVIQ2 2025
- EMEA sales surged 66% in Q3, driving growth despite declines in Americas and APAC.CEVIQ3 2024
- Strong sales and margins in Q2, led by APAC and EMEA, with positive momentum for H2 2024.CEVIQ2 2024
- Q1 2025 saw 14.6% sales growth, 34% EBITDA margin, and robust global demand.CEVIQ1 2025
- Q4 sales fell 7% but APAC growth and R&D investments support a positive outlook.CEVIQ4 2024
Next CellaVision earnings date
Q4 20264 Feb, 2027
CellaVision
Next CellaVision earnings date
Q4 20264 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CellaVision AB offers systems for automated and digital analysis of body fluids in health care services sector. It provides digital solutions for blood and body fluids analysis; image-based systems for microscopic analysis and clinical review of body fluids, such as peripheral blood film, and urine analysis; lab automation solutions; and software solutions, including Cellavision DM96, a complete solution that consists of an analyzer, instrument camera, computer, software environment with proprietary algorithms, ready-to-use reagents, and quality control material. The company also has integration solutions to hospital information systems and other laboratory systems. CellaVision AB was incorporated in 1994 and is headquartered in Lund, Sweden.